Salta alla navigazione principale
Salta alla ricerca
Salta al contenuto principale
Ordina per
Keyphrases
Advanced Stage Disease
7%
Adverse Risk
7%
Circulating Tumor DNA (ctDNA)
100%
Clinical Outcomes
7%
Clinical Trials
15%
Deep Sequencing
7%
Diagnosis-to-treatment Interval
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Disease Burden
7%
Disease Metrics
7%
Europe
7%
Event-free Survival
15%
Guard
7%
Hazard Ratio
7%
International Prognostic Index
46%
Inverse Correlation
7%
Metabolic Tumor Volume
23%
Multiple Centers
7%
Multivariable Cox Regression
7%
Non-modifiable Risk Factors
7%
Objectively Measured
7%
Patient Selection
7%
Prognostic Outcome
7%
Risk Factors
15%
Selection Bias
23%
Tumor Burden
7%
United States
7%
Univariable Analysis
7%
Medicine and Dentistry
Circulating Tumor DNA
100%
Clinical Trial
16%
Diffuse Large B-Cell Lymphoma
100%
Disease Burden
8%
Diseases
16%
Event Free Survival
16%
Hazard Ratio
8%
International Prognostic Index
50%
Malignant Neoplasm
8%
Neoplasm
33%
Patient Selection
8%
Proportional Hazards Model
8%
Selection Bias
25%
Pharmacology, Toxicology and Pharmaceutical Science
Circulating Tumor DNA
100%
Clinical Trial
16%
Diffuse Large B Cell Lymphoma
100%
Diseases
25%
Event Free Survival
16%
Malignant Neoplasm
8%
Neoplasm
33%
Immunology and Microbiology
B Cell
100%
Disease Burden
25%
Event Free Survival
50%
Metabolic Tumor Volume
75%
Tumor Volume
25%
Neuroscience
B Cell
100%
Circulating Tumor DNA
100%
Deep Sequencing
8%
Psychology
Hazard Ratio
100%
Proportional Hazards Regression Model
100%